Other languages Assembly Biosciences, Inc.

Equities

ASMB

US0453962070

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-24 pm EDT			5-day change	1st Jan Change
13.48 ^USD	+1.58%		-7.16%	+36.98%

Mar. 28	Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 19	Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	Jan. 19
Assembly Biosciences, Inc. Provides Anticipated Development Milestones for 2024	Jan. 04
Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board	Dec. 07
Assembly Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Assembly Biosciences, Inc. Appoints Anuj Gaggar as Chief Medical Officer	Nov. 08
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	23-10-17
Sector Update: Health Care	23-10-17
Gilead Sciences, Assembly Biosciences Working Together to Accelerate Development of New Antiviral Therapies	23-10-17
Gilead Sciences, Inc. and Assembly Biosciences, Inc. Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases	23-10-17
Assembly Biosciences Nominates Development Candidate Abi-6250, an Orally Bio Available HDV Entry Inhibitor	23-10-02
Assembly Biosciences, Inc. to Present Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting	23-09-19
Assembly Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Assembly Biosciences, Inc. Presents New Data Highlighting Herpes Simplex Virus Development Candidate Abi-5366 At the 47Th Annual International Herpesvirus Workshop	23-07-17
Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Assembly Biosciences Announces Additional Promising Data from Phase 1A Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate Abi-4334 and Provides Pipeline Update	23-04-18
Assembly Biosciences Files $150 Million Mixed Shelf	23-03-23
Assembly Biosciences, Inc. Provides Update on its Core Inhibitor Pipeline	23-03-22
Assembly Biosciences, Inc. Nominates First Herpesvirus Development Candidate ABI-5366, a Long Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes	23-02-15
Assembly Biosciences Reports 'Promising' Interim Results of Early Trials in Hepatitis B; Shares Rise	22-12-19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Assembly Biosciences, Inc.

Equities

ASMB

US0453962070

Other languages

Filters